NEW YORK, April 29 - Inpharmatica and Galapagos Genomics have agreed to collaborate on a drug discovery project using Inpharmatica's chemogenomics technology and Galapagos' adenoviral expression platform, the companies said today.
Under the agreement, Galapagos, of Mechelen, Belgiumwill provide Inpharmatica with targets for internal disease programs, which Inpharmatica, of London, will evaluate using PharmaCarta, its chemogenomics technology. Galapagos will also provide Inpharmatica acces to its PhenoSelect adenoviral expression platform for validation in-house some of the nuclear receptors that Inpharmatica has discovered.
The companies did not disclose the financial terms of the agreement.
